| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.097 | 0.003 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.095 | 0.004 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.004 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.004 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.13 | 0.004 |